Significantadvancements in the developmental pipeline across various oncologicaldisorders, infectious diseases and genetic disorders have amplified theinterest of various pharmaceutical establishments and have inspired researchgroups across the world, to focus their efforts on the development of RNAitherapeutics. Further, there are multiple pipeline candidates in mid tolate-stage (phase II and above) trials and are anticipated to enter the marketover the next 5-10 years.
To order this 350+ page report, which features 130+ figuresand 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Over170 RNAi therapeutics are currently under development
Nearly30% of pipeline drugs are in the clinical phase, while the rest are either inthe preclinical / discovery stage. The majority of pipeline drug candidates aredelivered using siRNA conjugated delivery technology platform to mitigatetargeted delivery to organ / cell.
More than 70% of ongoing clinical trials are beingconducted in North America and Europe
Intotal, we came across over 100 clinical trials that have been / are beingconducted across the globe. It is worth noting that around 40% of these trialswere observed to be phase II studies. Further, 75% of the active clinicaltrials being conducted in this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAitherapeutics since 2014
Majorityof these were patent applications (59%), followed by granted patents (40%). Itis worth highlighting that both industry and non-industry players are activelyinvolved in this domain. However, majority of the patents related to RNAitherapeutics were filed / granted by industry players (58%).
USD5.4+ billion invested by both private and public investors, since 2014
AroundUSD 3 billion was raised through secondary offerings, representing more than50% of the total capital raised by industry players till July 2019. Further, therehave been five instances of debt financing, accounting for more than USD 844million in financing of RNAi therapeutics related initiatives.
Around65 partnerships were inked since 2014
Maximumnumber of deals were reported in 2018. Around 30% of the deals were related tothe R&D agreements; this was followed by technology licensing agreements(27%).
RNAitherapeutics market is anticipated to increase at a CAGR of over 45% between2019-2030
Thisgrowth is anticipated to be primarily driven by the target specificity of thedrug candidates. North America (primarily the US) are expected to capture themajority share by 2030.
To request a samplecopy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/278/request-sample.html
§ Who are the leadingindustry players in this market?
§ What are the clinicalconditions for which RNAi therapeutics are being developed?
§ Who are the keyinvestors in the RNAi therapeutics market?
§ What kind ofcommercialization strategies are being adopted by RNAi therapeutics developers?
§ What are thedifferent promotional and reimbursement strategies used for RNAi therapeutics?
§ What are theprevalent R&D trends related to RNAi therapeutics?
§ What are the variousdelivery / technology platforms that are being used for the development of RNAitherapeutics?
§ What kind of partnershipmodels are used by stakeholders in this industry?
§ Who are the key serviceproviders in this field of therapeutics?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
§ Infectious diseases
§ Genetic disorders
§ Ophthalmic disorders
§ Hepatic disorders
§ Respiratory disorders
§ Route ofadministration
§ Key geographicalregions
§ North America
§ Asia Pacific and the Restof the World
§ Leading Players
Thereport features inputs from eminent industry stakeholder(s), according to whomRNAi therapeutics are promising domain of pharmaceutical industry. The reportincludes detailed transcripts of discussions held with the following expert(s):
§ Amotz Shemi (Chief Executive Officer, Silenseed)
Theresearch covers brief profiles, featuring an overview of the therapy, currentdevelopment status and clinical results. Each profile includes information ontherapeutic area, indication, targeted gene, route of administration, specialdesignations, mechanism of action, dosage, patent portfolio, technologyportfolio, clinical trials and recent developments (if available).
§ Souzhou Ribo LifeSciences
§ Olix Pharmaceuticals
§ Ariz PrecisionMedicine
§ Benitec Biopharma
Foradditional details, please visit
1. GeneTherapy Market (3rd Edition), 2019-2030
2. Global T-Cell (CAR-T,TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma ContractManufacturing Market (3rd Edition), 2019-2030
+1(415) 800 3415
+44 (122) 391 1091